Literature DB >> 24313243

Predictive factors for relapse in patients on buprenorphine maintenance.

Michael Ferri1, Alistair J Reid Finlayson, Li Wang, Peter R Martin.   

Abstract

BACKGROUND AND OBJECTIVES: Despite the dramatic increase in the use of buprenorphine for the treatment of opioid dependence, clinical outcomes of this treatment approach continue to need evaluation. This study examines factors associated with relapse and retention during buprenorphine treatment in a sample of opioid dependent outpatients.
METHODS: In a retrospective chart review of 62 patients with opioid dependence, relapse was determined by self-report, urine toxicology screens, and by checking the state controlled substance monitoring database. Data was analyzed using two-way tests of association and logistic regression.
RESULTS: Patients with comorbid anxiety disorders, active benzodiazepine use (contrary to clinic policy), or active alcohol abuse, were significantly more likely to relapse. Patients who relapsed were also more likely to be on a higher buprenorphine maintenance dose.
CONCLUSION: This study identifies relapse risk factors during buprenorphine treatment for opioid dependence. Future research is needed to determine whether modifying these factors may lead to improved treatment outcomes. © American Academy of Addiction Psychiatry.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24313243      PMCID: PMC3922612          DOI: 10.1111/j.1521-0391.2013.12074.x

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  10 in total

Review 1.  Clinical practice. Office-based treatment of opioid-dependent patients.

Authors:  David A Fiellin; Patrick G O'Connor
Journal:  N Engl J Med       Date:  2002-09-12       Impact factor: 91.245

Review 2.  Effect of buprenorphine dose on treatment outcome.

Authors:  Ayman Fareed; Sreedevi Vayalapalli; Jennifer Casarella; Karen Drexler
Journal:  J Addict Dis       Date:  2012

3.  Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.

Authors:  Roger D Weiss; Jennifer Sharpe Potter; David A Fiellin; Marilyn Byrne; Hilary S Connery; William Dickinson; John Gardin; Margaret L Griffin; Marc N Gourevitch; Deborah L Haller; Albert L Hasson; Zhen Huang; Petra Jacobs; Andrzej S Kosinski; Robert Lindblad; Elinore F McCance-Katz; Scott E Provost; Jeffrey Selzer; Eugene C Somoza; Susan C Sonne; Walter Ling
Journal:  Arch Gen Psychiatry       Date:  2011-11-07

4.  A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.

Authors:  R E Johnson; M A Chutuape; E C Strain; S L Walsh; M L Stitzer; G E Bigelow
Journal:  N Engl J Med       Date:  2000-11-02       Impact factor: 91.245

5.  Participant characteristics and buprenorphine dose.

Authors:  Maureen Hillhouse; Catherine P Canamar; Geetha Doraimani; Christie Thomas; Albert Hasson; Walter Ling
Journal:  Am J Drug Alcohol Abuse       Date:  2011-09       Impact factor: 3.829

6.  CDC grand rounds: prescription drug overdoses - a U.S. epidemic.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-01-13       Impact factor: 17.586

7.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors:  Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

8.  Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth.

Authors:  Geetha A Subramaniam; Diane Warden; Abu Minhajuddin; Marc J Fishman; Maxine L Stitzer; Bryon Adinoff; Madhukar Trivedi; Roger Weiss; Jennifer Potter; Sabrina A Poole; George E Woody
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-11       Impact factor: 8.829

9.  Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome.

Authors:  G Gerra; F Borella; A Zaimovic; G Moi; M Bussandri; C Bubici; S Bertacca
Journal:  Drug Alcohol Depend       Date:  2004-07-15       Impact factor: 4.492

10.  Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.

Authors:  Paul J Fudala; T Peter Bridge; Susan Herbert; William O Williford; C Nora Chiang; Karen Jones; Joseph Collins; Dennis Raisch; Paul Casadonte; R Jeffrey Goldsmith; Walter Ling; Usha Malkerneker; Laura McNicholas; John Renner; Susan Stine; Donald Tusel
Journal:  N Engl J Med       Date:  2003-09-04       Impact factor: 91.245

  10 in total
  18 in total

Review 1.  Pharmacogenetics of Opioid Use Disorder Treatment.

Authors:  Richard C Crist; Toni-Kim Clarke; Wade H Berrettini
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

Review 2.  Comorbidity of opioid-related and anxiety-related symptoms and disorders.

Authors:  Kirsten J Langdon; Kathrine Dove; Susan Ramsey
Journal:  Curr Opin Psychol       Date:  2019-01-04

3.  Indices of dentate gyrus neurogenesis are unaffected immediately after or following withdrawal from morphine self-administration compared to saline self-administering control male rats.

Authors:  Sarah E Bulin; Steven J Simmons; Devon R Richardson; Sarah E Latchney; Hannah M Deutsch; Sanghee Yun; Amelia J Eisch
Journal:  Behav Brain Res       Date:  2019-12-20       Impact factor: 3.332

4.  Long-term retention in Office Based Opioid Treatment with buprenorphine.

Authors:  Zoe M Weinstein; Hyunjoong W Kim; Debbie M Cheng; Emily Quinn; David Hui; Colleen T Labelle; Mari-Lynn Drainoni; Sara S Bachman; Jeffrey H Samet
Journal:  J Subst Abuse Treat       Date:  2016-12-30

5.  Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.

Authors:  Andrea Jakubowski; Tiffany Lu; Frank DiRenno; Benjamin Jadow; Angela Giovanniello; Shadi Nahvi; Chinazo Cunningham; Aaron Fox
Journal:  J Subst Abuse Treat       Date:  2020-09-22

6.  Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine.

Authors:  Zoe M Weinstein; Debbie M Cheng; Emily Quinn; David Hui; Hyunjoong Kim; Gabriela Gryczynski; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2016-11-05       Impact factor: 4.492

7.  Spiritual Well-Being and Associated Factors with Relapse in Opioid Addicts.

Authors:  Mohammad-Reza Noormohammadi; Masoud Nikfarjam; Fatemeh Deris; Neda Parvin
Journal:  J Clin Diagn Res       Date:  2017-03-01

8.  Opioid analgesic and benzodiazepine prescribing among Medicaid-enrollees with opioid use disorders: The influence of provider communities.

Authors:  Bradley D Stein; Joshua Mendelsohn; Adam J Gordon; Andrew W Dick; Rachel M Burns; Mark Sorbero; Regina A Shih; Rosalie Liccardo Pacula
Journal:  J Addict Dis       Date:  2016-07-22

9.  Impact of Current Pain Status on Low-Barrier Buprenorphine Treatment Response Among Patients with Opioid Use Disorder.

Authors:  Kelly R Peck; Taylor A Ochalek; Joanna M Streck; Gary J Badger; Stacey C Sigmon
Journal:  Pain Med       Date:  2021-05-21       Impact factor: 3.750

10.  Latent trajectories of anxiety and depressive symptoms among adults in early treatment for nonmedical opioid use.

Authors:  Jennifer D Ellis; Jill A Rabinowitz; Jonathan Wells; Fangyu Liu; Patrick H Finan; Michael D Stein; Denis G Antoine Ii; Gregory J Hobelmann; Andrew S Huhn
Journal:  J Affect Disord       Date:  2021-12-04       Impact factor: 4.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.